POST STROKE BRAIN RECOVERY TARGETING BLOOD FLOW AND VESSEL HEALTH
Dr Daniel Beard,
Senior Lecturer, University of Newcastle
Group Leader, Neurovascular Research Laboratory
New South Wales, Australia &
Visiting Scientist,
University of Oxford, United Kingdom &
Founder and Chief Scientific Officer
ShearFlow
RESEARCHER PROFILE
Filmed in Newcastle, Australia | May 2026
Dr Daniel Beard is a Senior Lecturer and Group Leader of the Neurovascular Research Laboratory at the University of Newcastle, with a distinguished career in stroke research. Dr Beard completed his PhD in Human Physiology in 2015, uncovering the impact of intracranial pressure on collateral vessel failure. He has held prestigious research and teaching roles at the University of Oxford and Charité Universitätsmedizin Berlin, contributing to international collaborations on neurovascular protection. His research has been supported by competitive grants, including an NHMRC Ideas Grant, and he has received numerous awards for innovation, research excellence and teaching excellence, including:
-Winner of the Challenger Pitch Prize at the Proto Axiom Challenger Summit (2024).
-Paul Dudley White International Scholar for the highest-ranked Australian abstract at the 2022 International Stroke Conference, New Orleans.
-Recipient of the Learning Design and Teaching Innovation Teaching Excellence Award and Mid-Career Teaching Award from the University of Newcastle (2024).
His most recent work focuses on understanding and improving collateral blood flow during ischaemic stroke. Notably, his groundbreaking work on shear stress and cerebral blood flow with renowned researchers at Harvard University, resulted in a patented nanoparticle therapy that selectively boosts brain perfusion during stroke, saving brain tissue and improving patient outcomes. This work was recently published in Advanced Science: https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202506276.
Dr Beard is Founder and Chief Scientific Officer of the University spinout ShearFlow that is now commercializing this technology to reach the clinic. This work aims to deliver targeted stroke therapies that could give patients a improved chance at recovery and a better quality of life.
Source: Supplied and adapted
https://orcid.org/0000-0002-3720-7588
-
Liver cancer & patient-derived tumour organoids
Dr Benjamin Dwyer is a translational cancer researcher driven by a clear purpose: to ensure discoveries made in the laboratory genuinely improve outcomes for patients.
Based at Curtin University, he established and now leads the organoid platform within the Liver Cancer Collaborative and directs the WA Organoid Innovation Hub, working at the intersection of biology, medicine and biotechnology to accelerate new treatments for liver cancer.
-
Impact of NextSense Institute Research in the field of sensory disabilities
NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.
NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations. The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.
-
Tyrosine Kinases in cancer recurrence
Dr Yu Yu leads the Oncology and Gynaecology Research Program at Curtin Medical Research Institute . Dr Yu is also a senior research fellow at Curtin Medical School.
Dr Yu Yu’s laboratory is working on better ways to treat cancers, particularly ovarian cancers which are resistant to conventional chemotherapy. The aims are for better informed treatment choice and reducing unnecessary exposure to ineffective chemotherapy and its potential adverse effects.
